Nutra Pharma Corp (NPHC)

[slbrown]

XenaCare Holdings Announces Upcoming Television and Radio Campaign for Over-the-Counter Pain Reliever, Cobroxin
Nutra Pharma Corp (BB) (OTCBB:NPHC)

Today : Monday 26 July 2010

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the branding, marketing and retail distribution of consumer healthcare products, announced today its upcoming Cobroxin advertising campaign to begin on July 28, 2010. The campaign is designed to support the rapidly growing network of retailers carrying Cobroxin, an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.

The advertising campaign, which is scheduled to begin on July 28, 2010, and run through December 2010, will consist of 2,515 television commercials in 60, 30 and 10 second spots appearing on major cable stations such as: CNN, Fox News, Food, Travel, ESPN, USA, Lifetime, CNBC, Comedy Central, AMC, History, Discovery, Fox Sports, Headline News (HLN), and Home and Garden. The commercials will also appear on the major power stations, NBC, CBS, and ABC, throughout Boston, Miami, Chicago, Dallas, San Francisco, Pittsburgh, Washington D.C., Nashville, Baltimore, Buffalo and New York. A selection of the shows on these will include news programs, "Ellen," "Oprah," "Dr. Oz," "David Letterman," and "Good Morning America."

In addition to the planned television commercials, the campaign will also include radio 770 radio spots during drive-time hours in Tampa, Atlanta, New York, Los Angeles and Houston.

"The timing of this campaign is important, as it comes when Cobroxin has full distribution across the United States," said Frank Rizzo, President of XenaCare. "We originally tested our television commercial on the Hallmark channel last month and in one week, it doubled our sales at several major retailers. With a total household reach of 100 million, we anticipate this campaign will be equally, if not more, successful in pulling Cobroxin sales through the current distribution chain," he added.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. The drug is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

All Natural
Non-Addictive
Non-Narcotic
Non-Opiate
Long Lasting
XenaCare Holdings was granted the exclusive license by Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin within the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.

These statements have not been evaluated by the FDA. These products are not intended to Diagnose treat or prevent any diseases.

http://www.XenaCareHoldings.com

http://www.Cobroxin.com

Cautionary Note Concerning Forward-Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward-looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company's current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.

Contact:

XenaCare Holdings

Frank Rizzo

561-496-6676

Email Contact